Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ACET

ACET - Adicet Bio, Inc. Stock Price, Fair Value and News

$8.44-0.10 (-1.17%)
Market Closed

83/100

ACET

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

83/100

ACET

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$12.66

Target 3M

$10.55

Target 6M

$11.39

ACET Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ACET Price Action

Last 7 days

4.6%

Last 30 days

7.2%

Last 90 days

-32.3%

Trailing 12 Months

-41.0%

ACET RSI Chart

ACET Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ACET Valuation

Market Cap

80.8M

Price/Earnings (Trailing)

-0.7

Price/Sales (Trailing)

0.43

EV/EBITDA

-0.48

Price/Free Cashflow

-0.81

ACET Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$12.66

Target 3M

$10.55

Target 6M

$11.39

ACET Fundamentals

ACET Revenue

Revenue (TTM)

180.4M

ACET Earnings

Earnings (TTM)

-115.0M

Earnings Growth (Yr)

11.88%

Earnings Growth (Qtr)

13.97%

ACET Profitability

EBT Margin

-63.76%

Return on Equity

-105.38%

Return on Assets

-81.87%

Free Cashflow Yield

-124.15%

ACET Investor Care

Shares Dilution (1Y)

85.99%

Diluted EPS (TTM)

-20

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202499.5M99.8M99.9M180.4M
202346.0M48.6M7.8M0
202238.7M33.9M73.8M68.3M
2021020.7M16.7M19.1M
20205.2M9.4M13.7M17.9M
2019000995.0K
20180008.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About Adicet Bio, Inc.

ACET
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.
 CEO
 WEBSITEadicetbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES132

Adicet Bio, Inc. Frequently Asked Questions

ACET is the stock ticker symbol of Adicet Bio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Adicet Bio, Inc. is 80.84 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ACET's fair value in chart for subscribers.

The fair value guage provides a quick view whether ACET is over valued or under valued. Whether Adicet Bio, Inc. is cheap or expensive depends on the assumptions which impact Adicet Bio, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACET.

As of Wed Jan 28 2026, ACET's PE ratio (Price to Earnings) is -0.7 and Price to Sales (PS) ratio is 0.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACET PE ratio will change depending on the future growth rate expectations of investors.